Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

NCT: NCT04400292 · ACTIVE_NOT_RECRUITING

NCT IDNCT04400292
StatusACTIVE_NOT_RECRUITING
Start Date2020-05-20
SponsorMemorial Sloan Kettering Cancer Center (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑